Shengnuo Pharmaceutical-B (02257) has filed a writ of subpoena against several former management of the Group, including Lu Yang, Dai Xiaochang and Ye Yongji

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shengnuo Pharmaceutical-B (02257) announced that on August 14, 2026, the Company and its direct wholly-owned subsidiary Shengnuo (Hong Kong) Limited (collectively, the “Plaintiff”) have filed a writ of summons (Case No.: HCA1427/2026) with the Hong Kong Special Administrative Region High Court (Court) to sue several former management of the Group, including Dr. Lu Yang, Dr. Dai Xiaochang and Mr. Ye Yongji (collectively, the “Defendants”).

These claims relate (as disclosed in these announcements) to a total principal investment of approximately $20 million (this investment) made by the Group in the independent investment portfolio of TradArt Flagship Investment SPC.

The plaintiff's claims against the defendant mainly include:

(1) The defendant breached its fiduciary duties and/or other liabilities owed to the plaintiff by virtue of the investment (including but not limited to making decisions, monitoring and/or handling of the investment);

(2) The defendant procured or participated in a payment, subscription matter or related arrangement without proper authorization, consent and/or due process; and

(3) Damages, equitable compensation, interest, costs, and further and/or other relief as the court deems appropriate.

The Company has instructed its legal advisors to take all necessary measures to protect the Group's legitimate rights and interests. The Company expressly reserves its right to take further action against any other former management, senior employee, or third party if necessary.